Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?

The U.S. Department of Health and Human Services has proposed piloting an “International Pricing Index” (IPI) payment model to reduce reimbursement levels for the Centers for Medicare & Medicaid Services (CMS), as well as proposing other reforms to long-standing policies regarding commercialized medicines. In a year with a record number of new medicines being approved to reach patients in the United States, such reforms introduce significant uncertainty for many investors’ valuation models. This session will feature drug developers, investors, and policy experts to explain the resource allocation implications if these reforms proceed and risks of shrinking the pipelines of new medicines for years to come unless alternative approaches can be introduced.

Moderator: James C. Greenwood, President and CEO, Biotechnology Innovation Organization (BIO)

  • Date:Tuesday, February 12
  • Time:11:00 AM - 11:55 AM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance:

    Click here.

Speakers
James C. Greenwood
Biotechnology Innovation Organization (BIO)
Paul Lammers
Triumvira Immunologics
Susan Peschin
Alliance for Aging Research
Peter Pitts
Center for Medicine in the Public Interest
Duane Schulthess
Vital Transformation
Erica Whittaker
UCB Ventures
Peter Young
Pappas Capital
Back